The first steps towards developing a vaccine against an insidious sexual transmitted infection (STI) have been accomplished by researchers at McMaster University.
Researchers at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster have developed the first widely protective vaccine against chlamydia, a common STI that is mostly asymptomatic but impacts 113 million people around the world each year and can result in infertility.
In a study, recently published in the journal Vaccine, the researchers show that a novel chlamydial antigen known as BD584 is a potential vaccine candidate for the most common species of chlamydia known as Chlamydia trachomatis.
As most C. trachomatis infections are asymptomatic, chlamydia can often go untreated and lead to upper genital tract infections, pelvic inflammatory disease, and infertility. This is why the promise of a vaccine would be extremely beneficial, says David Bulir, co-author of the study.
“Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans,” said Bulir, who just finished his PhD in medical sciences at McMaster.
“Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.”
In the research team’s study, BD584 was able to reduce chlamydial shedding – a symptom of C. trachomatis – by 95 per cent. The antigen also decreased hydrosalpinx, another C. trachomatis symptom which involves fallopian tubes being blocked with serous fluids, by 87.5 per cent.
The results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster’s Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton’s Research Institute where the work was performed.
Co-author and McMaster PhD student, Steven Liang, explains, “not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma.”
Trachoma is an eye infection caused by chlamydia and is the leading cause of preventable blindness affecting millions of people in many resource-poor regions of the world.
“The vaccine would be administered through the nose. This is easy and painless and does not require highly trained health professionals to administer, and that makes it an inexpensive solution for developing nations,” he said.
The next step is more testing for effectiveness against different strains of Chlamydia and in different formulations. The study was funded by the Canadian Institutes for Health Research.
The Latest on: Chlamydia
via Google News
The Latest on: Chlamydia
- Chlamydia Vaccine Clears Early Hurdle in Human Trialson August 16, 2019 at 4:02 pm
A new vaccine that might prevent the spread of chlamydia, the most common bacterial sexually transmitted disease in the world, was shown to be safe and effective in a phase 1 trial. The findings, ...
- The Week That Wasn't: Vaginal Steaming, Chlamydia Vaccine, Cat Allergieson August 16, 2019 at 7:38 am
Elsewhere on the Internet this week, you may have seen news stories about a new vaccine for chlamydia, a woman who tried to treat her vaginal prolapse with steam (yes, steam), and an experimental shot ...
- The first chlamydia vaccine has passed a major teston August 15, 2019 at 3:23 am
The first vaccine against chlamydia has passed its first test in humans. About three dozen healthy women were randomly assigned one of two versions of a chlamydia vaccine or a placebo treatment in a ...
- A Chlamydia Vaccine May Be Getting Closeron August 14, 2019 at 2:05 pm
A vaccine for the most common sexually transmitted infection has passed an early test on the path to public availability. Health researchers in the UK have developed a potential vaccine for chlamydia, ...
- New Chlamydia Vaccine Shows Promise In First Human Trialon August 14, 2019 at 6:54 am
Chlamydia is one of the most common sexually transmitted infections in the world, with doctors reporting 131 million new cases every year — but that number could drop dramatically thanks to a ...
- A chlamydia vaccine shows signs of success in an early trialon August 14, 2019 at 3:25 am
CNN — Scientists have taken a step towards a vaccine for chlamydia following a successful early trial. A vaccine developed by a British and Danish team was shown to be safe and effective during a ...
- Landmark chlamydia vaccine passes first stage of human trialson August 13, 2019 at 8:43 pm
Chlamydia infection strikes well over 100 million people every year, but a new vaccine offers hope in combatting it(Credit: iLexx/Depositphotos) The results from a Phase 1 trial into the safety of ...
- Chlamydia Vaccine Trial Proves to Be an Early Success: 'The Findings Are Encouraging'on August 13, 2019 at 7:05 pm
A vaccine for Chlamydia is potentially in sight. A team of British and Danish scientists recently completed a test of the vaccine they developed for the sexually transmitted infection and found it ...
- A Chlamydia Vaccine Shows Promise in Early Human Trialon August 13, 2019 at 2:25 pm
A vaccine for the most commonly reported sexually transmitted infection in the U.S.—the bacterial disease chlamydia—is now a substantial step closer to reality. On Monday, researchers reported ...
- The first chlamydia vaccine could soon be on its way. The common STI can lead to infertility, chronic pain, and an increased risk of HIV.on August 13, 2019 at 9:55 am
There are 1 million new STI cases globally every day, and many current antibiotics used to treat them are becoming antibiotic resistant.
via Bing News